Please login to the form below

Not currently logged in
Email:
Password:

generic drugs

This page shows the latest generic drugs news and features for those working in and with pharma, biotech and healthcare.

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance

and trastuzumab drugs in some emerging markets. ... small-molecule generic drugs in recent years.

Latest news

  • Teva cuts 25% of workforce, with Israel taking a heavy toll Teva cuts 25% of workforce, with Israel taking a heavy toll

    be successor laquinimod and an underperformance in its generic drug operations that have only been amplified by adding the Actavis business. ... The latest actions will see the number of generic drugs in the portfolio reduced, and a review of all R&D

  • Teva sheds R&D chief after new CEO takes the helm Teva sheds R&D chief after new CEO takes the helm

    also be combined into one global research group rather than being split between specialty and generic units. ... Schultz has taken up the CEO position at Teva at a challenging time, with sales slumping and thousands of jobs culled as a result of pressure

  • CETP inhibitor class finally dies as Merck abandons anacetrapib CETP inhibitor class finally dies as Merck abandons anacetrapib

    In the interim almost all of those brands have succumbed to generic competition, and new innovative drugs - such as the PCSK9 inhibitors from Amgen and Sanofi/Regeneron - have found it hard

  • Amgen's Mvasi is first FDA-approved cancer biosimilar Amgen's Mvasi is first FDA-approved cancer biosimilar

    Meanwhile, Avastin isn’t the only one of Roche's blockbuster cancer drugs at risk of generic competition. ... molecule drugs face generic competition - as they are still costly to produce and so are generally priced at less of a discount.

  • Teva poaches Lundbeck's Schultz as new CEO Teva poaches Lundbeck's Schultz as new CEO

    Schultz takes up the CEO position at Teva at a challenging time, with sales slumping and thousands of jobs culled as a result of pressure on its generic drugs business, mainly ... I am proud to be joining a company that helps millions of patients around

More from news
Approximately 3 fully matching, plus 290 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Roche will likely take the biggest loss in Europe, where nationalised healthcare systems are keen to

  • Deal Watch June 2016 Deal Watch June 2016

    The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... 8 generic drugs - filed ANDAs pending approval and an approved

  • Cost containment and the German market Cost containment and the German market

    They represent an established instrument of cost control, especially in the generic segment, as 93% of all drugs under rebate contract are generics. ... Focusing on patented drugs, the price difference to the generic segment is significant.

  • Deal Watch February 2016 Deal Watch February 2016

    Licensor Acquired/Licensee Acquirer. Product/Technology. Deal Type. Headline ($m). Meda/Mylan. portfolio of branded, OTC and generic drugs.

  • Social media and inflation penalties for generic drugs Social media and inflation penalties for generic drugs

    Today. Per the legislation, generic drugs will have to pay an additional rebate on top of the basic rebate. ... As a result, 340B prices for generic drugs may be lowered as Medicaid URAs become higher.

More from intelligence
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest appointments

  • Elite Pharma names Actavis VP as CEO Elite Pharma names Actavis VP as CEO

    These include 12 generic drugs already approved by the US Food and Drug Administration (FDA) but are yet to be marketed. ... An additional generic product is under review. “ Nasrat has broad experience in both branded and generic pharmaceuticals as

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics